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metastases are the major cause of death from melanoma, a skin cancer that has the fastest 
rising incidence of any malignancy in the Western world. molecular pathways that drive 
melanoblast migration in development are believed to underpin the movement and ultimately 
the metastasis of melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase 
guanine nucleotide exchange factor, have a melanoblast migration defect during development 
evidenced by a white belly. moreover, these P-Rex1 − / −  mice are resistant to metastasis when 
crossed to a murine model of melanoma. mechanistically, this is associated with P-Rex1 driving 
invasion in a Rac-dependent manner. P-Rex1 is elevated in the majority of human melanoma 
cell lines and tumour tissue. We conclude that P-Rex1 has an important role in melanoblast 
migration and cancer progression to metastasis in mice and humans. 
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Melanoma is an aggressive skin cancer characterized by its resistance to chemotherapy. Its incidence has doubled over the past two decades in the Western world. Patients 
who have primary melanomas with a Breslow thickness  > 4 mm 
have a dramatically increased incidence of metastasis and reduced 
survival1. Progression to melanoma is driven primarily by onco-
genic mutations of BRAF (50–60%) or NRAS (15–30%)2–4, but 
must be accompanied by further genetic and epigenetic changes 
in gene expression, most commonly the loss of tumour suppres-
sors p16INK4A or PTEN5,6. Present treatments with conventional 
chemotherapies have had no impact on overall survival, with the 
BrafV600E-targeted therapy, vemurafenib (PLX4032), recently giv-
ing cause for encouragement7,8. However, there remains a deficit of 
effective treatment strategies for other melanoma types, while treat-
ment resistance to vemurafenib has been reported in melanomas 
coexpressing NrasQ61K with oncogenic BrafV600E (refs 9 and 10).
PREX1 encodes the P-Rex1 Dbl family of Rho GTPase guanine 
nucleotide exchange factors (GEFs). Rho family small GTPases com-
prise a major branch of the Ras superfamily of small GTPases (for 
example, RhoA, Rac1 and Cdc42)11. P-Rex1 is a Rac-specific GEF 
stimulated by PI3K-stimulated phosphatidylinositol (3,4,5)-trisphos-
phate production and the β-gamma subunits of the heterotrimeric-G 
proteins (Gβγ), both of which bind to P-Rex1 (refs 12–14). It has also 
been identified as a transcriptional target of extracellular signal-regu-
lated kinase (ERK) signalling across a panel of melanoma cell lines15. 
Rac, the main effector of P-Rex1 activity, is involved in the induction 
of actin-mediated membrane ruffling and lamellipodia formation 
at the leading edge of cell migration, and its aberrant activation has 
been implicated in tumour cell invasion and metastasis16,17.
P-Rex1 has not previously been characterized in genetically 
modified animal models of cancer that can genetically and patho-
logically recapitulate the human disease. Earlier studies using cancer 
cell lines have implicated a role in prostate, breast and ovarian can-
cer18–21. Here we demonstrate that P-Rex1 is necessary for migration 
of melanoblasts during mouse development, it facilitates metastasis 
formation in an NrasQ61K-driven mouse model of melanoma, and it 
is upregulated in human melanoma-derived cell lines and tissue.
Results
P-Rex1-deficient mice have a white belly phenotype. We first 
investigated the in vivo relevance of P-Rex1 by further analyses of a 
P-Rex1 − / −  mouse22. We identified a ‘white belly’ phenotype with 
100% penetrance in P-Rex1 − / −  mice on a pure C57BL6 background 
(Fig. 1a). The phenotype persisted when P-Rex1 − / −  mice were crossed 
with TyrNrasQ61K/° transgenic mice (TyrNrasQ61K/°; P-Rex1 − / − ), 
a major driver mutation in melanoma (Fig. 1a)23. Depigmentation 
affecting the feet was also observed in TyrNrasQ61K/°; P-Rex1 − / −  
mice (Fig. 1a). Tissue sections of bellies from P-Rex1 − / −  and 
TyrNrasQ61K/°; P-Rex1 − / −  mice suggested that no melanocytes were 
present throughout the skin in the white belly area (Fig. 1b). Thus 
expression of NrasQ61K was not able to overcome the ‘white belly’ 
induced by ablation of PREX1.
P-Rex1 deficiency impairs normal melanoblast migration. The 
belly, feet and tail are the furthermost points of mouse melanoblast 
migration from the neural crest during embryogenesis. In line with 
this and the role of P-Rex1 in activation of Rac, we hypothesized 
that the areas of depigmentation in P-Rex1 − / −  mice predominantly 
represented a defect of melanoblast migration during embryogene-
sis, rather than an impaired proliferative capacity or inability to pro-
duce melanin pigment in adult melanocytes. To test this hypothesis, 
we first ensured the presence of PREX1 in melanoblasts (Fig. 2a).
To address whether melanoblast number or migratory behav-
iour was altered, we next analysed P-Rex1 − / −  and TyrNrasQ61K/°; 
P-Rex1 − / −  mice that had been intercrossed with mice carrying the 
DCT-lacZ transgene, a melanoblast reporter line24. Melanoblast 
sparing of the feet and belly was apparent in both DCT-lacZ 
P-Rex1 − / −  and DCT-lacZ TyrNrasQ61K/°; P-Rex1 − / −  mice at E15.5, 
excluding a defect in melanin production as a cause for their 
depigmentation (Fig. 2b,c).
Using a melanoblast migration assay, which compared differ-
ences in distal melanoblast migration at various points of develop-
ment (Fig. 2d; Supplementary Fig. S1a), analysis of E13.5 and E15.5 
embryos showed a statistical difference in melanoblast migration 
between DCT-lacZ P-Rex1 − / −  and DCT-lacZ P-Rex1 + / +  mice (Fig. 2e; 
Supplementary Fig. S1b). This was not overcome by NrasQ61K/° expres-
sion (Fig. 2f; Supplementary Fig. S1b). Consistent with a migratory 
defect, melanoblasts on the flank of the DCT-lacZ P-Rex1 − / −  mice had 
fewer protrusions than DCT-lacZ P-Rex1 + / +  controls (Fig. 2g,h).
A melanoblast cell number assay at E13.5 showed no differ-
ence in cell numbers between DCT-lacZ P-Rex1 − / −  and DCT-lacZ 
P-Rex1 + / +  mice unless DCT-lacZ P-Rex1 − / −  mice were intercrossed 
with TyrNrasQ61K/° mice (Supplementary Figs S2a,b). There was 
however a small but significant reduction of E15.5 cell numbers 
in DCT-lacZ P-Rex1 − / −  mice compared with DCT-lacZ P-Rex1 + / + , 
and DCT-lacZ TyrNrasQ61K/°; P-Rex1 − / −  compared with DCT-lacZ 
TyrNrasQ61K/°; P-Rex1 + / +  mice (Fig. 2i,j). This difference is likely to 
represent a proliferative deficit in P-Rex1 − / −  melanoblasts: cell death 
was not observed in E15.5 whole skin from P-Rex1 + / +  or P-Rex1 − / −  
mouse embryos, using a live ex vivo imaging technique that we have 
previously described (Supplementary Movies 1–3)25. Moreover, 
a significant reduction in E15.5 cell numbers was again seen in 
P-Rex1 − / −  embryos compared with P-Rex1 + / +  controls using this 
technique (Supplementary Fig. S2c). Collectively, these results 
would be consistent with previous reports of a role for Rac in cell 
cycle control, as well as the proliferative defect observed when 
P-Rex1 was knocked down in breast cancer cell lines21,26,27. They sug-
gest that a small proliferative defect is preceded by a marked migra-
tion defect in P-Rex1 − / −  mice.
P-Rex1 deficiency impairs metastasis in a melanoma mouse 
model. The imprint of past migratory behaviour of neural crest–
derived melanocyte precursors has been suggested to confer a pro-
pensity of primary melanomas to establish distant metastases28–30. 
We therefore crossed P-Rex1 − / −  mice with a genetically modified 
model of metastatic malignant melanoma, TyrNrasQ61K/°; INK4a − / −  
mice, to assess whether P-Rex1 may also be important for primary 
melanoma development and/or metastasis23.
TyrNrasQ61K/°; INK4a − / − ; P-Rex1 + / +  mice developed primary 
melanoma and metastasis with a similar penetrance and latency to 
that previously described (Fig. 3a). Immunohistochemistry (IHC) 
was carried out on primary melanomas taken from P-Rex1 + / +  
and P-Rex1 − / −  mice to confirm P-Rex1 expression in tumours 
(Fig. 3b,c). Seven out of ten primary melanomas from P-Rex1 + / +  
mice showed staining for P-Rex1, compared with zero out of nine 
samples from P-Rex1 − / −  mice. All metastases from P-Rex1 + / +  mice 
displayed immunoreactivity for P-Rex1 similar to that of MelanA 
(11 samples; lung, liver and brain; Fig. 3d).
Although Rac function has been shown to be required for pri-
mary squamous cell skin and lung tumour development31,32, we 
observed no difference in incidence, latency or tumour burden of 
primary melanomas between TyrNrasQ61K/°; INK4a − / − ; P-Rex1 + / +  
and TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  mice (Table 1; Fig. 3e,f). 
However, a significant reduction in melanoma metastasis was 
observed in the TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  cohort, with 
the number of metastases in control TyrNrasQ61K/°; INK4a − / − ; 
P-Rex1 + / +  mice the same as previously reported (P = 0.001; χ2-test; 
Table 1). TyrNrasQ61K/o; INK4a − / − ; P-Rex1 − / −  mice also had an 
improved overall survival (Fig. 3g). These data are consistent with 
the mouse melanoblast data, suggesting that P-Rex1 is a central 
component of migration and invasion.
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Although we are unable to categorically exclude the possibility 
that our melanoma brain lesions are not primary melanocytic neo-
plasms of the central nervous system (CNS), a significant reduction 
in metastases was still seen when these lesions were excluded from 
our analysis (Table 1). Clearly they at least invade the brain paren-
chyma from either a blood-borne metastasis or the lepto-menin-
geal site of origin in primary CNS melanoma (Fig. 3d). In support 
of them being genuine metastases, no NrasQ61K mutations were 
observed in a previous study of human primary CNS melanoma33.
We next further explored the prometastatic role of endogenous 
P-Rex1 in melanoma by deriving melanocyte cell lines from the early 
pup skin of TyrNrasQ61K/°; INK4a − / − ; P-Rex + / +  and TyrNrasQ61K/°; 
INK4a − / − ; P-Rex1 − / −  mice. When injected via tail vein (TV) into 
C57BL6 mice, two out of four mice treated with TyrNrasQ61K/°; 
INK4a − / − ; P-Rex1 − / −  melanocytes were found to have metastases, com-
pared with five out of five mice who were treated with TyrNrasQ61K/°; 
INK4a − / − ; P-Rex + / +  cells (Supplementary Table S1, Supplementary 
Fig. S3). A significant reduction in metastatic frequency was observed 
on histological analyses of the cohort injected with TyrNrasQ61K/°; 
INK4a − / − ; P-Rex1 − / −  melanocytes, with a clear reduction in meta-
static tumour burden also seen (Supplementary Fig. S3a,b). Moreo-
ver, we observed a propensity of the TyrNrasQ61K/°; INK4a − / − ; 
P-Rex + / +  cells to metastasize to distant viscera (kidney, liver, heart 
and spleen), metastases that were not seen in the mice TV-treated with 
TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  cells (Supplementary Table S1, 
Supplementary Fig. S3c–g). Collectively, these results suggested that 
endogenous P-Rex1 can facilitate frequency, growth and organ spread 
of metastases in melanoma from the intravasation stage of the meta-
static cascade.
These data in genetically modified models of cancer were 
also supported by analyses of immuno-deficient mice which 
were injected subcutaneously with a number of different human 
melanoma-derived cell lines (Supplementary Fig. S4a,b, Supple-
mentary Table S2). In total, 17/24 cell lines developed tumours fol-
lowing injection, with 4/24 also forming metastases. Quantitative 
reverse transcription (RT)–PCR (Supplementary Methods) analysis 
revealed that, of the cell lines with P-Rex1 mRNA levels above the 
median (‘high’ P-Rex1), nearly all went on to develop tumours in 
immuno-deficient mice (Supplementary Figs. S4a). This included 
all mice that developed metastases, and notably, the two NrasQ61K 
and BrafV600E cell lines with the highest P-Rex1 mRNA levels both 
developed metastases. Statistical evaluation of these results con-
firmed that high P-Rex1 was 100% statistically sensitive for detect-
ing those nude mice that developed metastases (Supplementary 
Table S3; P = 0.005; χ2-test). P-Rex1 levels were highest in cell lines 
that form metastases after averaging P-Rex1 levels in cell lines 
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Figure 1 | P-Rex1-deficient mice have a ‘white belly’ phenotype. (a) Belly and feet of P-Rex1 + / +  and P-Rex1 − / −  mice in combination with both nras + / +  
and nrasQ61K/° transgenic modification. (b) Photomicrographs (haematoxylin and eosin) of belly skin from the four genotypes represented in (a). normal 
melanocyte situation in a C57BL6 mouse is in the hair follicles (black arrows). melanocytes and deposition of melanin in the dermis (red arrow) and 
adipose tissue (red arrowheads) are seen in nrasQ61K/° mice. scale bar, 100 µm.
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that formed no tumours, tumours or metastases (Supplementary 
Fig. S4b). The lowest expression occurred in those cell lines that 
do not form tumours in immuno-deficient mice (Supplementary 
Fig. S4b).
P-Rex1 is upregulated and drives invasion in human melanoma. 
To test the relevance of our data to human melanomagenesis, we 
first examined the expression of P-Rex1 in established human 
melanoma cell lines derived from primary or metastatic dis-
ease. Compared with normal human melanocytes (NHM), there 
was marked P-Rex1 overexpression in nearly all of the cell lines 
(Fig. 4a). Moreover, the three cell lines with clearly the highest 
P-Rex1 expression (CHL1, SK-Mel119 and Mel224) were all derived 
from a metastatic source (Supplementary Table S4), supporting our 
above analysis that showed high P-Rex1 mRNA was sensitive for the 
development of metastases in TV-treated immuno-deficient mice 
(Supplementary Fig. S4).
We next assessed whether increased P-Rex1 activity in humans is 
also related to melanoma progression: this possibility was raised by 
both the sensitivity of high P-Rex1 mRNA for nude mouse metastasis 
development and the increased expression of P-Rex1 observed in 
melanoma-derived cell lines compared with normal melanocytes. 
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Figure 2 | P-Rex1 − / −  mice have a defect in melanoblast migration. (a) RT–PCR of P-Rex1 mRnA in E14.5 embryo skin following FACs selection of cells 
enriched for melanoblasts (yellow fluorescent protein, YFP + ) compared with the rest of the embryo skin (YFP − ). Tyrosinase and Dct controls confirm 
melanoblast enrichment. (b) E15.5 representative pictures comparing melanoblast migration to the belly in 5-bromo-4-chloro-3-indolyl-β-d-galactoside 
(X-gal)-stained embryos. scale bars, 500 µm. (c) Comparison of melanoblast migration along the forepaw in X-gal-stained embryos at E15.5. A migratory 
deficit is evident in both P-Rex1 − / −  (with either nras + / +  or nrasQ61K/°) embryos. scale bars, 500 µm. (d) schematic picture detailing quantification of 
melanoblast migration in the forepaw at E15.5. Levels 1 to 6 from top to bottom represent areas of 500×500 µm. melanoblasts counted at each level and 
numbers compared between genotypes. (e,f) Comparison of melanoblast migration between P-Rex1 + / +  (blue bars) and P-Rex1 − / −  (red bars) mice at levels 
1 to 6 (as detailed in d). upper panel (e) represents nras + / +  embryos (*P = 0.01/0.02, levels 2/3; mann–Whitney test, n = 5), lower panel (f) represents 
nrasQ61K/° embryos (*P = 0.02/0.02/0.01, levels 1/2/3; mann–Whitney test, n = 5; all box and whiskers plots: boxes represent 25th–75th percentiles of 
given value, lines represent median values). (g) Representative pictures at E15.5 of melanoblast morphology and protrusions (red arrows) on the flank of 
X-gal-stained embryos. scale bars, 100 µm. (h) Quantification and comparison of percentage of cells with 1 +  protrusions: P-Rex1 + / +  (n WT, blue bars) and 
P-Rex1 − / −  mice (n Hom, red bars; left-hand panel; *P = 0.05, mann–Whitney; n = 4); and TyrnrasQ61K/°; P-Rex1 + / +  (Y WT, blue bars) and TyrnrasQ61K/°; 
P-Rex1 − / −  (Y Hom, red bars) mice (right-hand panel; *P = 0.03; mann–Whitney, n = 4). (i) schematic picture detailing quantification of melanoblast cell 
numbers at E15.5. Areas represented: 1×3 mm. (j) Comparison of E15.5 melanoblast numbers between P-Rex1 + / +  (n WT, blue bars) and P-Rex1 − / −   
(n Hom, red bars) mice (left-hand panel), and also between TyrnrasQ61K/°; P-Rex1 + / +  (Y WT, blue bars) and TyrnrasQ61K/°; P-Rex1 − / −  (Y Hom, red bars) 
mice (right-hand panel) (left panel: *P = 0.01; right panel: *P = 0.01; mann–Whitney test, n = 5). Gapdh, glyceraldehyde-3-phosphate dehydrogenase;  
WT, wild type.
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IHC for P-Rex1 was performed on human tissue specimens from 
skin and melanoma: although P-Rex1 expression was not detectable 
in melanocytes in normal skin (3 out of 3 specimens), we consist-
ently detected it in biopsies of primary melanomas (112 out of 141 
specimens) and melanoma lymph node metastases (8 out of 9 speci-
mens; Fig. 4b; Supplementary Fig. S5). These data provided further 
evidence of a role for P-Rex1 in human melanoma progression, and 
were consistent with our previous findings in mice.
One potential way that P-Rex1 could drive progression and 
metastatic spread is through an increased invasive capacity con-
ferred by its RacGEF activity. To examine this, we knocked down 
endogenous P-Rex1 in the CHL1 human melanoma cell line, where 
P-Rex1 was upregulated (Fig. 4a). Consistently we observed that 
three-dimensional (3D) matrigel invasion was diminished follow-
ing knockdown of endogenous P-Rex1 (Fig. 4c–e). This result was 
also reproducible in the WM793 human melanoma cell line used in 
our RT–PCR data (Supplementary Fig. S6a–c). As P-Rex1 is over-
expressed in the majority of human melanoma cell lines, we used 
the previously described melanocyte cell line derived from early 
pup skin of TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  mice to examine 
invasion in a cell line where P-Rex1 is not endogenously expressed. 
These P-Rex1 − / −  cell lines, which were genetically manipulated 
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Figure 3 | P-Rex1 − / −  mice have significantly reduced metastases in a TyrNrasQ61K/°; INK4a − / −  murine melanoma model. (a) Primary and 
metastatic melanomas arising in TyrnrasQ61K/°; InK4a − / −  transgenic mice. Red arrowhead: pigmented primary skin melanoma; white arrowheads: 
multiple pigmented lung metastases; red arrow: pigmented liver metastasis; white arrow: large pigmented brain lesion. (b) melanA and P-Rex1 
immunohistochemical expression in primary melanomas of P-Rex1 + / +  mice. Varying levels of P-Rex1 expression can be seen in mouse melanomas (pink 
staining) n = 10. (c) melanA and P-Rex1 immunohistochemical expression in primary melanomas of P-Rex1 − / −  mice. no P-Rex1 expression was observed in 
melanomas from these mice n = 9. (d) melanA and P-Rex1 immunohistochemical expression in melanoma metastases from P-Rex1 + / +  control mice. upper 
four panels show expression in brain lesions, while lower four panels show expression in lung metastases (pink staining) n = 11. (e) Comparison of primary 
tumour burden between TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / +  (blue bar) and TyrnrasQ61K/°; InK4a − / − ; P-Rex1 − / −  (red bar) mice (P = 0.43, mann–Whitney, 
n = 29; small asterisks represent outlying data; box and whiskers plot: box represent 25th–75th percentile of given value, line represents median value). 
(f) Kaplan–meier analysis of primary melanoma latency between TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / +  (black line, n = 27) and TyrnrasQ61K/°; InK4a − / − ; 
P-Rex1 − / −  (red line, n = 18) cohorts (P = 0.156, log-rank test). (g) Kaplan–meier curves detailing significant improvement in survival of TyrnrasQ61K/°; 
InK4a − / − ; P-Rex1 − / −  cohort (red line) compared with TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / +  cohort (black line; *P = 0.017, log-rank test, n = 30 for each 
cohort). WT, wild type.
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to overexpress empty vector (‘pLHCX’), failed to invade in 3D 
matrigel and organotypic assays unless they were re-constituted to 
express ectopic levels of P-Rex1 (‘P-Rex1’; Fig. 4f–i). Expression of 
ectopic levels of GEF-dead P-Rex1 (‘P-Rex1 GD’) failed to pheno-
copy the invasive phenotype of cells with re-constituted wild-type 
P-Rex1, confirming the RacGEF activity of P-Rex1 as a downstream 
mechanism (Fig. 4f–i). Interestingly, ectopic expression of another 
RacGEF described in melanoma, TIAM1, also failed to phenocopy 
the invasion seen with P-Rex1 expression (Fig. 4f–h)34. These results 
showed that the RacGEF activity of P-Rex1 may have a unique role 
among RacGEFs: it functions as a vital component of invasion for 
cells of the melanocyte lineage, a mechanism by which it can drive 
melanoma progression and metastases.
Discussion
Here we evaluated the role of a Rac-specific Rho GTPase GEF, 
P-Rex1, for the first time in a genetically modified animal model of 
cancer. In particular, we have examined its role in melanoma pro-
gression, invasion and metastasis. First, we showed that P-Rex1 has a 
role in progression with our human cell line and IHC analysis show-
ing P-Rex1 upregulation in tumour compared with NHMs. Second, 
matrigel and organotypic invasion assays confirmed that P-Rex1 is 
a key component of invasion in both humans and mice, channelled 
through its RacGEF activity. Finally and most importantly, we have 
determined that genetic ablation of PREX1 impairs melanoma 
metastases in TyrNrasQ61K; INK4a − / −  mice. Taken together, these 
results confirm that P-Rex1 upregulation is an important compo-
nent of melanoma progression, invasion and metastatic signal-
ling, supporting the value of pharmacological inhibition of P-Rex1 
activation of Rac for treatment of metastatic or high-risk primary 
melanomas.
Mechanistic experiments in our study have highlighted the key 
similarities between the molecular machinery involved in the move-
ment of melanoblasts and that of metastatic melanoma cells. Genetic 
ablation of PREX1 impaired migration of melanoblasts, evidenced 
by a ‘white belly’ phenotype that reflected the diminished metastases 
seen in TyrNrasQ61K; INK4a − / −  mice. A potential pathophysiologi-
cal link with incidence of metastases therefore fits the physiological 
role of P-Rex1 seen in melanoblast migration. Moreover, the pre-
dominant role of P-Rex1 in invasion and migration is reflected by its 
presence in motile melanoblasts and its upregulation in metastatic 
melanoma cell lines.
Other studies have previously suggested a role for P-Rex1 in 
prostate, breast and ovarian cancer18–21, with key similarities exist-
ing between our study and that of Sosa et al.19 in particular. Notably, 
this report identified P-Rex1 as having particular relevance to the 
specific ER +  ( + / −  ErbB2) subset of breast tumours. One key area 
to focus on next will be to assess whether the in vivo tumourigenic 
effects of P-Rex1 are specific to melanomas driven by oncogenic 
Nras, or reproducible in BrafV600E-driven tumours: this is a clear pos-
sibility given the identification of P-Rex1 as a transcriptional target 
of ERK signalling in melanoma15. These previous P-Rex1 cancer 
studies have also shown an effect on both primary tumour growth 
and lymph node metastases using xenotransplantation of human 
cancer cell lines into immuno-deficient mice. However, this tech-
nique often fails to recapitulate the characteristics of the original 
tumour they are meant to represent, and their use for informative 
studies of novel cancer target validation has become increasingly 
contentious35–37. A key advance in our study is therefore the charac-
terization of P-Rex1 in animal models of cancer, which recapitulate 
the common human genetics of the disease.
Strategies for inhibiting RAS have long been a therapeutic chal-
lenge9. Our findings suggest that targeting P-Rex1 signalling might 
have great relevance to tumours driven or codriven by oncogenic 
RAS, with potential benefits extending to all melanomas10. There is 
limited but growing evidence that Rho GTPase guanine nucleotide 
exchange factors are tractable targets for the development of small-
molecule inhibitors17. The lack of P-Rex1 expression in most other 
normal human cell types offers a clear therapeutic window and basis 
for selective cytotoxicity14,37.
Here we have identified P-Rex1 as a novel anticancer target in 
melanoma. Our experiments provide stringent preclinical validation 
of P-Rex1 in cancer using informative genetically defined mouse 
models that recapitulate common human mutations. Together with 
recent observations in other cancers18–21, we suggest that P-Rex1 is 
an important therapeutic target for the treatment of a diverse spec-
trum of human cancers.
Methods
Embryo analysis and β-galactosidase staining. All studies were conducted in 
accordance with UK home office guidelines. Time of gestation was calculated  
using noon on the day of detection of a vaginal plug as E0.5, but also noting and 
comparing the external appearance of the embryo. Embryos were dissected at 
E15.5 then fixed in 0.25% glutaraldehyde at 4 °C for 45 min on a rolling platform. 
Embryos washed in PBS at 4 °C for 15 min on a rolling platform, detergent washed 
(2 mM MgCl2, 0.01% Na-deoxycholate, 0.02% NP-40 in PBS) at room temperature 
three times (30 min, 15 min two times). β-Galactosidase substrate (1 M MgCl2, 
0.02% NP-40, 0.01% Na-deoxycholate, 0.04% 5-bromo-4-chloro-3-indolyl-β-d-
galactoside, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6) was then added to the embryos, 
which were incubated in darkness overnight. Embryos were postfixed in 4% 
paraformaldehyde for 2 h at 4 °C.
For cell number assays, the area used for quantification of cell numbers rep-
resented the most proximal point of melanoblast migration from the neural crest 
which could be accurately assayed. Counting melanoblasts in more distal regions 
would have introduced a migrational component to the assay which we aimed  
to avoid.
Mouse treatment and survival cohorts. A total of 80 TyrNrasQ61K/°; INK4a − / −  
and 10 C57BL6 mice were monitored for up to 18 months for the development of 
melanoma and signs of metastasis. All mice were checked thrice weekly for the 
development of malignant melanoma or any other pathology. End point criteria 
were melanomas ≥15 mm, ulcerating melanomas, cachexia, significant weight loss, 
or weakness and inactivity. Upon meeting these criteria, mice were euthanized. 
Mice were examined for the presence of frank metastasis upon dissection, but 
also visualization of haematoxylin-and-eosin (H&E)-stained sections for further 
identification of microscopic metastases. Organs/tumours were removed and fixed 
in 10% buffered formalin overnight at room temperature. Fixed tissues were paraf-
fin embedded, and 5 mm sections were placed on sialynated/poly-l-lysine slides for 
immunohistochemical analysis. Lymph node metastases were not included in  
this analysis due to difficulty in distinguishing them from normal melanocyte 
populations that can be found in lymphoid tissue.
Table 1 | P-Rex1 − / −  dramatically reduces incidence of metastasis in an TyrNrasQ61K/°; INK4a − / −  transgenic murine melanoma 
model.
Genotypes 
 
Mice with  
primary  
melanoma
Average  
age (days) 
Mice with  
melanoma  
metastases
Mice with melanoma  
metastases, excluding  
brain lesions
TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / + 30/41 184 13/30 6/30
TyrnrasQ61K/°; InK4a − / − ; P-Rex1 − / − 30/42 211 1/30 1/30
P=0.001 P=0.044
Table detailing numbers of mice within both TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / +  and TyrnrasQ61K/°; InK4a − / − ; P-Rex1 − / −  cohorts suffering from primary and metastatic melanoma (χ2-test). metastatic 
sites other than brain for TyrnrasQ61K/°; InK4a − / − ; P-Rex1 + / +  cohort were lungs (four mice), liver (three mice), peritoneum (one mouse); TyrnrasQ61K/°; InK4a − / − ; P-Rex1 − / −  metastasis was in lungs.
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For TV-injections into C57BL6 mice, cultured cells were maintained in antibi-
otic-free media for 1 week before injection. Cells were detached with trypsin, then 
blocked through suspension in complete culture media supplemented  
with 10% fetal bovine serum (FCS). Cells subjected to two rounds of washing, 
involving centrifugation at 100 g for 5 min followed by resuspension in 1× Hanks’ 
Balanced Salt Solution (HBSS). Cells were finally resuspended in HBSS to a  
concentration of 1×107 cells ml − 1 and TV injected at 1×106 cells per animal in a 
volume of 100 µl.
Immunohistochemistry. For P-Rex1, serial sections were unmasked in 10 mM 
citric acid, pH 6.0, with boiling for 30 min. Remaining steps were carried out with 
Thermo ScientificUltraVision LP Detection System (Thermo Fischer Scientific). 
Primary antibody was incubated in the presence of 5% normal goat serum (Dako). 
Antigens were developed with Vector Red Alkaline Phosphatase Substrate Kit 
(Vector Labs). The following antibody dilutions were used: P-Rex1, 1:100; MelanA, 
1:100. ‘Positive’ staining refers to any level of staining visualized.
Antibodies. Rabbit polyclonal raised against human P-Rex1 (HPA001927) and 
mouse monoclonal specific to β-actin (clone AC-15, A1978) were obtained from 
Sigma-Aldrich. Mouse monoclonal specific to Melan-A (clones DT101  +  BC199, 
ab731) was obtained from Abcam Ltd.
Human tissues. A tissue microarray was performed on archival paraffin patient 
samples from St Vincent’s University Hospital, Dublin, Ireland. Quadruplicate 
cores from 141 consecutive melanoma patients (1994–2007) were used to construct 
the tissue microarray. Further samples were received from Radboud University 
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Figure 4 | P-Rex1 is upregulated in human melanoma where it drives invasion through its RacGEF activity. (a) Western blots illustrating endogenous 
expression of P-Rex1 in a panel of human melanoma-derived cell lines. Cell lines with driver mutations in NRAS and BRAF are represented, along with cell 
lines that are WT for both. nHm, normal human melanocytes. (b) P-Rex1 expression increases with more aggressive disease. Photomicrographs of human 
tissue specimens of normal skin, primary and metastatic melanoma, immunohistochemically labelled against P-Rex1 or the melanocyte marker melanA. 
Ln, lymph node. scale bars, 90 µm. (c) silencing P-Rex1 by siRnA as shown by western blot analysis. A mock transfection and scramble siRnA were 
used as controls. (d) Comparison of representative matrigel invasion assays of CHL1 human melanoma cell lines treated with control or P-Rex1-specific 
siRnA oligonucleotides. (e) Quantification of cells invading beyond 45 µm in matrigel invasion assays of CHL1 human melanoma cell lines treated with 
control (‘siControl’) versus P-Rex1 (‘siP-Rex1’)-specific siRnA oligonucleotides (*P = 0.005, mann–Whitney test; n = 3; error bars,  ± s.e.m). (f) Western 
blot confirming relative expression of ‘P-Rex1’, ‘P-Rex1 GD’ and ‘Tiam1’ cells is well matched. (g) Representative matrigel invasion assays comparing 
melanocytes derived from early pup skin of TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  mice, genetically modified to overexpress P-Rex1 (‘P-Rex1’), empty vector 
(‘pLHCX’), GEF-dead P-Rex1 (‘P-Rex1 GD’) or Tiam1 (‘Tiam1’). (h) Left panel: quantification of cells invading beyond 45 µm in matrigel invasion assays of 
pLHCX versus P-Rex1 versus P-Rex1 GD cells (*P ≤ 0.0001 for both comparisons, mann–Whitney test; n = 3). Right panel: quantification of cells invading 
beyond 45 µm in matrigel invasion assays of pLHCX versus P-Rex1 versus Tiam1 cells (*P ≤ 0.0001 for both comparisons, mann–Whitney test; n = 3; 
error bars for both panels,  ± s.e.m.). (i) Representative organotypic invasion assays comparing TyrNrasQ61K/°; INK4a − / − ; P-Rex1 − / −  parental melanocytes 
genetically manipulated to overexpress wild-type P-Rex1 (‘P-Rex1’), empty vector (‘pLHCX’) and ‘P-Rex1 GD’ (n = 3; scale bars, 90 µm).  
WT, wild type.
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Medical Center, Nijmegen, the Netherlands. All patient specimens were used in 
accordance with institutional and national policies at the respective locations.
Statistical analyses. Statistical analyses in mice were carried out using Minitab 
version 15 for Windows. Cell migration, invasion and cell number differences 
were determined using Mann–Whitney test. Distinction of metastasis and primary 
melanoma incidence was achieved using χ2-testing. Survival differences were de-
termined with log-rank testing. All P-values were considered significant at P ≤ 0.05. 
All appropriate value sets were tested for normality using a Kolmogorov–Smirnoff 
normality test.
Cell culture. NHMs were maintained in Mln254 medium (M-254-500, Cascade 
Biologics) supplemented with human melanocyte growth serum (S-002-5, Cascade 
Biologics) and penicillin/streptomycin at 100 U ml − 1. Mel224, Mel505, SK-Mel 2, 5, 
23, 119, 147 and 187, CHL-1, A375 and WM266.4 were maintained in Dulbec-
co’s modified Eagle medium supplemented with 10% FCS, L-glutamine at 200 µM 
and penicillin/streptomycin at 100 U ml − 1. SBCL2, Lu1205, WM852, MeWo, 
Dauv-1, Gerlach, 888mel, 501mel, MNT-1, WM 35, 278, 793, 902b, 1552c and 
1789 were maintained in RPMI 1640 supplemented with 10% FCS and penicillin/
streptomycin at 100 U ml − 1.
For melanocyte isolation from mice, pup skin was dissected at P2 then placed 
in ice-cold PBS. Quickly it was cut into pieces and incubated in 1.5 ml of col-
lagenase types 1 and 2 at 37 °C, 5% CO2 for approximately 25–50 min. Contents 
transferred into 10 ml wash buffer (1× HBSS, 1 mM CaCl2, 0.005% DNase) and 
centrifuged at 200 g for 5 min at room temperature. Sample resuspended in 2 ml 
dissociation buffer, placed in small Petri dish and incubated at 37 °C, 5% CO2 
for 10 min. Thereafter, sample was put through an 18G then 20G needle and 
transferred into 10 ml wash buffer for 10 min. Supernatant centrifuged at 200 g for 
5 min at room temp, pellet resuspended in 2 ml PBS, then re-centrifuged at 200 g 
for 5 min. Resuspended and maintained in RPMI 1640 medium supplemented with 
10% FCS, l-glutamine at 200 µM and penicillin/streptomycin at 100 U ml − 1.
siRNA treatments and RacGEF constructs. Stable cell lines expressing Myc-
epitope tagged human P-Rex1 were generated by retroviral infection using the 
modified Retro-X retroviral expression system (Clontech). An HpaI restriction 
site, followed by Kozak consensus translation initiation site was introduced to the 
5′ end of the coding sequence of myc-P-Rex1 (ref. 13), myc-P-Rex1 GEF-dead13 or 
myc-Tiam1 by PCR (5′-GTTAACCACCATGGAGCAGAAGCTGATC-3′), with a 
ClaI restriction site introduced to the 3′ end in the same reaction (P-Rex1/P-Rex1 
GEF-dead: 5′-CCATCGATTCAGAGGTCCCCATCCACCGG-3′), with pCMV-
P-Rex1, pCMV-P-Rex1 GEF-dead or pcDNA3.1-myc-Tiam1 used as template. In 
each case, the HpaI–ClaI DNA fragments produced were subcloned into HpaI and 
ClaI sites of the pLHCX retroviral expression vector. High-titre, replication-in-
competent retroviral particles encoding the RNA of interest were produced in the 
Phoenix Ampho packaging line (Orbigen), for human target cells, and the Phoenix 
Eco packaging line (Orbigen) for murine target cells. Subsequent infection of target 
lines resulted in transfer of the coding region of interest, along with a selectable 
marker. Pooled cell lines stably expressing the construct of interest were isolated 
by selection with hygromycin-B (500 µg ml − 1) over multiple passages. Control 
lines were infected with retroviral particles expressing an empty pLHCX control 
vector transcript, and subjected to an identical selection procedure. Expression 
of the ectopically introduced proteins of interest was determined by western blot 
and immunodetection with both epitope-tag-specific and protein-specific primary 
antibodies.
Transient knockdown of target proteins was achieved through consecutive 
rounds of liposome-mediated transfection with the appropriate small interfer-
ing RNA (siRNA) oligonucleotides, 48 h apart. Liposomal transfection reagent 
(301702, HiPerFect), non-targeting control oligonucleotides (1027281, AllStars 
Negative Control) and P-Rex1-specific oligonucleotides (SI00692405, Hs_PREX1_
3; SI03144449, Hs_PREX1_5; SI03246383, Hs_PREX1_6) were obtained from 
Qiagen Ltd.
Invasion assays. For inverted Matrigel invasion assays38, Matrigel protein matrix 
(BD Bioscience) was allowed to polymerize in Transwell permeable inserts (Corn-
ing Ltd) over a period of 60 min at 37 °C. Inserts were inverted, and cells seeded di-
rectly onto the filter surface in complete growth medium. Cells were then allowed 
to adhere over a period of 3 h at 37 °C, after which both non-adherent cells and 
residual growth medium were removed with three washes in appropriate  
serum-free medium. Finally, inserts were placed in serum-free tissue culture 
medium (containing 10% FCS) above the Matrigel matrix to function as a che-
moattractant. In the case of siRNA-mediated transient knockdown experiments, 
invasion assays were prepared 24 h after the second round of lipofection. At 72-h 
postseeding, invasive cells that had entered Matrigel were stained with the fluo-
rescent live-cell dye Calcein-AM, and visualized through confocal microscopy of 
optical sections obtained in the z-plane at 15 µm intervals. Quantification was with 
the Area Calculator plugin for ImageJ (http://rsbweb.nih.gov/ij/).
For organotypic invasion assays39, approximately 7.5×104 ml − 1 primary human 
fibroblasts were embedded in a 3D matrix of rat tail collagen I. Rat tail tendon 
collagen solution was prepared by the extraction of tendons with 0.5 M acetic 
acid to a concentration of ~2 mg ml − 1. Detached, polymerized matrix (2.5 ml) in 
35-mm Petri dishes was allowed to contract for approximately 6 days in complete 
media (DMEM, supplemented with 10% FCS; Invitrogen) until the fibroblasts 
had contracted the matrix to ~1.5 cm diameter. Subsequently, TyrNrasQ61K/°; 
INK4a − / − ; P-Rex1 − / −  melanocytes, stably expressing either control vector, human 
P-Rex1 or a GEF-dead mutant of human P-Rex1, were seeded onto the prepared 
matrix in complete media (4×104 cells per assay) and allowed to grow to conflu-
ence for 5 days. The matrix was then mounted on a metal grid and raised to the 
air/liquid interface resulting in the matrix being fed from below with complete 
media that was changed every 2 days. After 15 days, the cultures were fixed with 
4% paraformaldehyde and processed by standard methods for haematoxylin and 
eosin staining. 
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